Stay informed with the latest updates for the inheritable blood disorders community. IndustryGrifols Changes Name of Hemophilia A StudyFeb 1, 2014 IndustryPhase 1 Trial Begins for Alnylam's ALN-AT3Feb 1, 2014 IndustryBiogen and Swedish Orphan Biovitrum Announce Results of Longer-…Jan 1, 2014 IndustryBaxter Seeks Pediatric Indication from FDA for RIXUBISJan 1, 2014 IndustryProgress and Delay for Biogen's Longer-Lasting rFVIII TherapyDec 1, 2013 IndustryEnrollment Complete for Baxter's PROLONG-ATE StudyDec 1, 2013 IndustryFDA Approves BLA for Novo Nordisk's New rFVIII ProductNov 1, 2013 IndustryBoehringer Fills Trial for Interferon-free HCV TherapyOct 1, 2013 IndustrySernova and Medicyte Collaborate on Hemophilia A TherapyOct 1, 2013 IndustryNovo's rFVIII Receives Recommendation for EMA Marketing ApprovalOct 1, 2013 IndustryFDA Grants Orphan Drug Status to Alnylam's Hemophilia TherapySep 1, 2013 IndustryBayer Announces 2013 BHAP WinnersAug 1, 2013 IndustryNovo Nordisk Reports Additional Findings from HERO StudyAug 1, 2013 IndustryFDA Gives Priority Review to Gilead's HCV Drug SofosbuvirJul 1, 2013 IndustryFDA Accepts Application for Biogen's Longer-Lasting FVIII ProductJun 1, 2013 Pagination First page Previous page … Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Page 21 … Next page Last page
